focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-SSE says no break-up decision after report of Elliott pressure

Mon, 20th Sep 2021 08:33

* SSE backs current strategy

* Shares closed higher on Monday

* The Telegraph reported company was close to splitting

* Source says Elliott is among top 5 shareholders in SSE
(Adds background, context, chart, updates shares)

By Muvija M

Sept 20 (Reuters) - Britain's SSE has not made a
decision to split itself up, the renewable power and networks
group said on Monday in response to a newspaper report that it
was close to doing so after months of pressure from U.S.
activist investor Elliott.

A source close to the situation confirmed that Elliott was
one of the top five investors in the blue-chip company, holding
a stake just under the 5% threshold that would require formal
disclosure.

SSE, which declined to comment on Elliott's reported
involvement or stakeholding, said it would update investors on
growth plans in due course. It is scheduled to report interim
results in mid-November.

SSE shares have gained nearly 9% this year, with more than
6% of the rise having come after a media report in early August
about Elliott buying a stake. The company has a market valuation
of more than 17 billion pounds ($23.2 billion).

SSE has been sharpening its focus on renewable power
generation and electricity networks after the sale of its retail
division to OVO Energy. It plans to invest 7.5 billion pounds
($10.3 billion) in low-carbon projects up to 2025.

By splitting SSE's renewables business from networks the
company could attract a couple of billion pounds from investors
who are ESG-focussed, the source said.

The source added that conversations between Elliott and SSE
are understood to have been constructive.

On Monday the stock closed 0.4% higher, outshining the main
bourse that ended down 0.8%.

SSE's statement followed a Telegraph report on Friday https://bit.ly/3lE1yQe
that the company was close to splitting into two separate
blue-chip companies.

"The Board remains fully focused on strategic choices which
will drive shareholder value from the wealth of net zero
opportunities the company is creating," SSE said.

"SSE is currently building more offshore wind than any
company in the world, expanding internationally, and investing
in the low-carbon electricity infrastructure."

New York-based Elliott, which in the past had pushed for
changes at Premier-Inn owner Whitbread, has more
recently targeted London-listed pharmaceutical giant GSK
.

The hedge fund has been in talks with SSE's board to
separate the company's wholesale networks business from its
renewables operations for more than a year, the Telegraph report
added, citing unidentified sources.

Elliott declined a Reuters request for comment on the
report.

Energy companies in Britain and across the world are under
the spotlight amid a surge in gas prices.
($1 = 0.7313 pounds)

(Reporting by Chris Peters and Muvija M in Bengaluru
Editing by Saumyadeb Chakrabarty, Mark Potter and Keith Weir)

More News
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.